PharmaTelevision - Genera Biosystems: Diagnostics Come of Age

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Genera Biosystems: Diagnostics Come of Age

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In early 2008 Genera Biosystems was floated on the ASX and, despite the current economic environment, the CEO, Allen Bollands is feeling positive about the company’s future. He predicts that a ‘golden age’ for diagnostics companies is just around the corner and discusses how he intends to keep Genera Biosystems at the forefront of the industry, making the most of the company's current cash position and strong platform technology.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Genera Biosystems's Diagnostics business platform.

Fintan Walton:

Hello and welcome to PharmaVentures business review here in Melbourne Australia. On this show I have Allen Bollands who is the CEO of Genera Biosystems. Welcome to the show.

Allen Bollands:

Good morning.

Fintan Walton:

Allen Bollands, Genera Biosystems is a company based in Australia. It's a diagnostic business. Could you tell us what that diagnostic business is about in particular the platform on which the company rests it's intellectual property rights?

Allen Bollands:

Sure. Genera Biosystems was incorporated in 2002 and originally it was a SNPs business. We were performing SNPs assays mostly for academic clients. But really that business was not a profitable business. It was difficult to make any money particularly with academics. However the technology that under pinned that was ideal for developing molecular diagnostics test more broadly and in fact colleagues of our chief scientific officer who went on to work in commercial pathology came to us and said look would you mind making it a test for human papillomavirus which is our first test. And so the platform that we have is essentially it is a silica based bead platform and these beads act as a surface upon which Hybridization reactions can occur, PCR Hybridization reactions can occur and what we are able to do is to code our beads in such a way by reference to size and by reference to color and then multiplex multiple different clusters of beads together and one cluster bead detects one analyte and in that way we were able to detect up to about a 150 analytes in the same in the same reaction.

Fintan Walton:

So that allows you to do a broad based diagnostic?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Allen Bollands

Chief Executive Officer

Dr Allen Bollands was appointed Chief Executive Officer of Genera Biosystems Limited in November 2005. He brought to Genera substantial commercial leadership experience in the life sciences industry having held senior positions with SmithKline Beecham and Novartis in Australia, Europe and the United States. He has a particularly strong background in marketing, sales, product development and business development. He was Chief Executive of Adelaide-based Repromed, and has been an independent consultant to several other Australian biotech companies.

Genera Biosystems

Genera Biosystems Limited is an Australia-Based company that is principally engaged in the development and commercialization of a portfolio of molecular diagnostics test technologies in Australia. The Company's focus is to utilize it's platform deoxyribonucleic acid analysis technologies to exploit the lucrative molecular diagnostics market. Genera Biosystems is currently developing a suite of molecular diagnostic testing products.